B+
Bull case
25%
Probability
Target price
$12.00
+17.5% vs current
NVAX
NovavaxBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$8.50
-16.7% vs current
B-
Bear case
25%
Probability
Target price
$5.00
-51.0% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+31.7
Score
AI commentary
Overall sentiment is cautious-neutral. Primary-source evidence is real and reasonably strong, but it mostly supports a monitoring thesis rather than a directional breakout call: Novavax has improved cost structure, meaningful cash, and credible partner optionality, yet its most important 2026 upside buckets are explicitly unguided and heavily partner-driven. The deterministic prior is neutral with modestly negative medium-term expected returns and above-mid uncertainty, which fits a low-conviction watchlist stance rather than a strong bullish recommendation.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalyst1H26 partner-revenue conversion checkHigh impact
The first 2026 reporting cycle is the near-term proof point on whether Novavax can convert its partner-led model into cleaner recurring revenue: management framed 2026 adjusted revenue at $230-$270 million, including $70-$80 million of R&D reimbursement and $50-$60 million of other partner revenue that includes a $30 million Pfizer upfront payment received in 1Q26, while 2025 results were boosted by prior APA settlements [#10-K-2026-02-26].
2026-09-30eventSanofi-led 2026-2027 COVID season visibilityHigh impact
Management said Novavax will sell 2026-2027 commercial supply to Sanofi and is eligible for high-teens to low-twenties royalties on Sanofi sales, but gave no 2026 guidance for Sanofi supply sales, royalties, or combo/Matrix-M milestones; any concrete disclosure on those items could move the stock because they sit outside the current framework [#10-K-2026-02-26].
2027-12-31catalystMatrix-M monetization beyond core COVID economicsHigh impact
Novavax now has a second optionality bucket beyond seasonal Nuvaxovid: the January 2026 Pfizer Matrix-M license carries a $30 million upfront payment, up to $500 million of development and sales milestones, and tiered royalties, while Sanofi combination and adjuvant programs still leave sizable milestone pools outstanding, but timing is uncertain and partner-controlled [#10-K-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology